{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T11:00:42Z","timestamp":1788778842345,"version":"build-2803163510"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T00:00:00Z","timestamp":1758499200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T00:00:00Z","timestamp":1758499200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s11033-025-11059-0","type":"journal-article","created":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T14:06:22Z","timestamp":1758549982000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Novel and recurrent mutations in exon 8 of natural killer group 2D (NKG2D) gene among chronic myeloid leukemia patients and their potential role in pathogenesis"],"prefix":"10.1007","volume":"52","author":[{"given":"Aya Abdulrahman","family":"Bahjat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5168-6802","authenticated-orcid":false,"given":"Khder Hussein","family":"Rasul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,22]]},"reference":[{"issue":"1","key":"11059_CR1","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-022-00289-8","volume":"11","author":"Z Du","year":"2022","unstructured":"Du Z et al (2022) Modified dendritic cell-derived exosomes activate both NK cells and T cells through the NKG2D\/NKG2D-L pathway to kill CML cells with or without T315I mutation. Exp Hematol Oncol 11(1):36","journal-title":"Exp Hematol Oncol"},{"issue":"24","key":"11059_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20246141","volume":"20","author":"L Bavaro","year":"2019","unstructured":"Bavaro L et al (2019) Mechanisms of disease progression and resistance to tyrosine kinase inhibitor therapy in chronic myeloid leukemia: an update. Int J Mol Sci 20(24):6141","journal-title":"Int J Mol Sci"},{"issue":"22","key":"11059_CR3","doi-asserted-by":"publisher","first-page":"6606","DOI":"10.1158\/1078-0432.CCR-18-3373","volume":"25","author":"FE Nicolini","year":"2019","unstructured":"Nicolini FE et al (2019) Evaluation of residual disease and TKI duration are critical predictive factors for molecular recurrence after stopping Imatinib first-line in chronic phase CML patients. Clin Cancer Res 25(22):6606\u20136613","journal-title":"Clin Cancer Res"},{"issue":"6","key":"11059_CR4","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1002\/ajh.25792","volume":"95","author":"E Jabbour","year":"2020","unstructured":"Jabbour E, Kantarjian H (2020) Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring. Am J Hematol 95(6):691\u2013709","journal-title":"Am J Hematol"},{"issue":"5","key":"11059_CR5","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1007\/s12185-021-03117-7","volume":"113","author":"H Ureshino","year":"2021","unstructured":"Ureshino H (2021) Treatment-free remission and immunity in chronic myeloid leukemia. Int J Hematol 113(5):642\u2013647","journal-title":"Int J Hematol"},{"issue":"1","key":"11059_CR6","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1146\/annurev-immunol-032712-095951","volume":"31","author":"DH Raulet","year":"2013","unstructured":"Raulet DH et al (2013) Regulation of ligands for the NKG2D activating receptor. Annu Rev Immunol 31(1):413\u2013441","journal-title":"Annu Rev Immunol"},{"issue":"9","key":"11059_CR7","doi-asserted-by":"publisher","first-page":"3859","DOI":"10.3390\/cimb44090265","volume":"44","author":"KH Rasul","year":"2022","unstructured":"Rasul KH et al (2022) Assessment of T cell receptor complex expression kinetics in natural killer cells. Curr Issues Mol Biol 44(9):3859\u20133871","journal-title":"Curr Issues Mol Biol"},{"issue":"2","key":"11059_CR8","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/s41577-022-00732-1","volume":"23","author":"NK Wolf","year":"2023","unstructured":"Wolf NK, Kissiov DU, Raulet DH (2023) Roles of natural killer cells in immunity to cancer, and applications to immunotherapy. Nat Rev Immunol 23(2):90\u2013105","journal-title":"Nat Rev Immunol"},{"issue":"7","key":"11059_CR9","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1002\/eji.202049028","volume":"51","author":"L Quatrini","year":"2021","unstructured":"Quatrini L et al (2021) Human NK cells, their receptors and function. Eur J Immunol 51(7):1566\u20131579","journal-title":"Eur J Immunol"},{"issue":"2","key":"11059_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/biom10020301","volume":"10","author":"J Wang","year":"2020","unstructured":"Wang J, Li C-D, Sun L (2020) Recent advances in molecular mechanisms of the NKG2D pathway in hepatocellular carcinoma. Biomolecules 10(2):301","journal-title":"Biomolecules"},{"issue":"24","key":"11059_CR11","doi-asserted-by":"publisher","DOI":"10.3390\/ijms242417545","volume":"24","author":"L Wei","year":"2023","unstructured":"Wei L, Xiang Z, Zou Y (2023) The role of NKG2D and its ligands in autoimmune diseases: new targets for immunotherapy. Int J Mol Sci 24(24):17545","journal-title":"Int J Mol Sci"},{"key":"11059_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.713158","volume":"12","author":"MB Fuertes","year":"2021","unstructured":"Fuertes MB, Domaica CI, Zwirner NW (2021) Leveraging NKG2D ligands in immuno-oncology. Front Immunol 12:713158","journal-title":"Front Immunol"},{"issue":"6","key":"11059_CR13","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.3390\/cells10061420","volume":"10","author":"J Siemaszko","year":"2021","unstructured":"Siemaszko J, Marzec-Przyszlak A, Bogunia-Kubik K (2021) NKG2D natural killer cell receptor\u2014a short description and potential clinical applications. Cells 10(6):1420","journal-title":"Cells"},{"issue":"4","key":"11059_CR14","doi-asserted-by":"publisher","first-page":"438","DOI":"10.3390\/cancers11040438","volume":"11","author":"L Gimeno","year":"2019","unstructured":"Gimeno L et al (2019) NKG2D polymorphism in melanoma patients from southeastern Spain. Cancers 11(4):438","journal-title":"Cancers"},{"issue":"5","key":"11059_CR15","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1080\/01443615.2020.1798906","volume":"41","author":"A Abdian Asl","year":"2021","unstructured":"Abdian Asl A et al (2021) Association between rs1049174 NKG2D gene polymorphism and idiopathic recurrent spontaneous abortion in Iranian women: a case-control study. J Obstet Gynaecol 41(5):774\u2013778","journal-title":"J Obstet Gynaecol"},{"key":"11059_CR16","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1007\/s12185-017-2294-1","volume":"106","author":"R Hara","year":"2017","unstructured":"Hara R et al (2017) NKG2D gene polymorphisms are associated with disease control of chronic myeloid leukemia by dasatinib. Int J Hematol 106:666\u2013674","journal-title":"Int J Hematol"},{"issue":"3","key":"11059_CR17","first-page":"346","volume":"45","author":"S Sabri","year":"2016","unstructured":"Sabri S, Keyhani M, Akbari MT (2016) Whole exome sequencing of chronic myeloid leukemia patients. Iran J Public Health 45(3):346","journal-title":"Iran J Public Health"},{"issue":"1","key":"11059_CR18","doi-asserted-by":"publisher","first-page":"20.e1","DOI":"10.1016\/j.jtct.2021.09.019","volume":"28","author":"K Ido","year":"2022","unstructured":"Ido K et al (2022) Effect of donor NKG2D polymorphism on relapse after haploidentical transplantation with post-transplantation cyclophosphamide. Transplant Cell Ther 28(1):20.e1-20.e10","journal-title":"Transplant Cell Ther"},{"issue":"10","key":"11059_CR19","first-page":"2064","volume":"9","author":"H Liu","year":"2019","unstructured":"Liu H et al (2019) Role of NKG2D and its ligands in cancer immunotherapy. Am J Cancer Res 9(10):2064\u20132078","journal-title":"Am J Cancer Res"},{"key":"11059_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/biology12081079","author":"G Tan","year":"2023","unstructured":"Tan G, Spillane KM, Maher J (2023) The role and regulation of the NKG2D\/NKG2D ligand system in cancer. Biology. https:\/\/doi.org\/10.3390\/biology12081079","journal-title":"Biology"},{"key":"11059_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1597731","volume":"16","author":"Y Jin","year":"2025","unstructured":"Jin Y et al (2025) T cell-mediated immune surveillance conferred by latent Epstein-Barr virus genes suppresses a broad spectrum of tumor formation through NKG2D-NKG2DL interactions. Front Immunol 16:1597731","journal-title":"Front Immunol"},{"issue":"1","key":"11059_CR22","doi-asserted-by":"publisher","DOI":"10.3390\/immuno5010009","volume":"5","author":"E Boneva","year":"2025","unstructured":"Boneva E, Shivarov V, Ivanova M (2025) A concise review of the role of the NKG2D receptor and its ligands in cancer. Immuno 5(1):9","journal-title":"Immuno"},{"issue":"2","key":"11059_CR23","doi-asserted-by":"publisher","first-page":"69","DOI":"10.5306\/wjco.v12.i2.69","volume":"12","author":"MM Sampaio","year":"2021","unstructured":"Sampaio MM et al (2021) Chronic myeloid leukemia-from the Philadelphia chromosome to specific target drugs: a literature review. World J Clin Oncol 12(2):69\u201394","journal-title":"World J Clin Oncol"},{"issue":"4","key":"11059_CR24","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","volume":"34","author":"A Hochhaus","year":"2020","unstructured":"Hochhaus A et al (2020) European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia 34(4):966\u2013984","journal-title":"Leukemia"},{"issue":"7809","key":"11059_CR25","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1038\/s41586-020-2308-7","volume":"581","author":"KJ Karczewski","year":"2020","unstructured":"Karczewski KJ et al (2020) The mutational constraint spectrum quantified from variation in 141,456 humans. Nature 581(7809):434\u2013443","journal-title":"Nature"},{"issue":"5","key":"11059_CR26","doi-asserted-by":"publisher","first-page":"442","DOI":"10.15252\/emmm.201506055","volume":"8","author":"S Diederichs","year":"2016","unstructured":"Diederichs S et al (2016) The dark matter of the cancer genome: aberrations in regulatory elements, untranslated regions, splice sites, non-coding RNA and synonymous mutations. EMBO Mol Med 8(5):442\u2013457","journal-title":"EMBO Mol Med"},{"issue":"10","key":"11059_CR27","doi-asserted-by":"publisher","first-page":"S283","DOI":"10.47391\/JPMA-BAGH-16-64","volume":"74","author":"KA Wahhab Ali","year":"2024","unstructured":"Wahhab Ali KA, Ahmed AA, Mohammed ST (2024) Determination of serum myeloperoxidase (MPO) and lactate dehydrogenase (LDH) as a tumour marker in chronic myeloid leukaemia (CML). J Pak Med Assoc 74(10):S283\u2013s286","journal-title":"J Pak Med Assoc"},{"issue":"3","key":"11059_CR28","doi-asserted-by":"publisher","first-page":"445","DOI":"10.2174\/1574892816666210222152126","volume":"16","author":"TS Hailemariam","year":"2021","unstructured":"Hailemariam TS et al (2021) BCR-ABL transcript level as compared to LDH and uric acid among chronic myeloid leukemic patients. Recent Pat Anticancer Drug Discov 16(3):445\u2013455","journal-title":"Recent Pat Anticancer Drug Discov"},{"issue":"1","key":"11059_CR29","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1186\/s12885-024-12282-x","volume":"24","author":"F Urgessa","year":"2024","unstructured":"Urgessa F et al (2024) Hematological, clinical, cytogenetic and molecular profiles of confirmed chronic myeloid leukemia patients at presentation at a tertiary care teaching hospital in Addis Ababa, Ethiopia: a cross-sectional study. BMC Cancer 24(1):530","journal-title":"BMC Cancer"},{"issue":"1","key":"11059_CR30","doi-asserted-by":"publisher","first-page":"78","DOI":"10.54005\/geneltip.1348459","volume":"34","author":"S Demircio\u011flu","year":"2024","unstructured":"Demircio\u011flu S et al (2024) Impact of hemoglobin, leucocyte and thrombocyte levels at diagnosis on the survival outcomes of chronic myeloid leukemia patients. Genel T\u0131p Dergisi 34(1):78\u201382","journal-title":"Genel T\u0131p Dergisi"},{"issue":"2","key":"11059_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.modpat.2023.100406","volume":"37","author":"D Rivera","year":"2024","unstructured":"Rivera D et al (2024) Aleukemic chronic myeloid leukemia without neutrophilia and thrombocytosis: a report from the BCR::ABL1 pathology group. Mod Pathol 37(2):100406","journal-title":"Mod Pathol"},{"issue":"4","key":"11059_CR32","doi-asserted-by":"publisher","first-page":"78","DOI":"10.14715\/cmb\/2025.71.4.10","volume":"71","author":"Naa-Z Ali","year":"2025","unstructured":"Ali Naa-Z et al (2025) Evaluation of blood components and their association with Interleukin-18 in chronic myeloid leukemia. Cell Mol Biol 71(4):78\u201387","journal-title":"Cell Mol Biol"},{"issue":"3","key":"11059_CR33","doi-asserted-by":"publisher","first-page":"295","DOI":"10.15537\/smj.2024.45.3.20230776","volume":"45","author":"AM Alshahrani","year":"2024","unstructured":"Alshahrani AM et al (2024) Hematological malignancies: prevalence and hematological characteristics in a single center in Southern Saudi Arabia. Saudi Med J 45(3):295\u2013306","journal-title":"Saudi Med J"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-025-11059-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-025-11059-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-025-11059-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,28]],"date-time":"2025-12-28T05:02:54Z","timestamp":1766898174000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-025-11059-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,22]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["11059"],"URL":"https:\/\/doi.org\/10.1007\/s11033-025-11059-0","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,22]]},"assertion":[{"value":"10 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no conflict of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The research project (No: 4\u00a0S\/311, September 3, 2024) has been approved by the Human Ethics Committee of the College of Science at Salahaddin University-Erbil (Erbil, Iraq), meeting the Helsinki Declaration criteria. Each patient and healthy participant is required to sign a consent form before joining the study, and if they have any disabilities, we have asked their legal representatives to sign on their behalf.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Ethical committee and consent for participation"}}],"article-number":"941"}}